GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aarey Drugs & Pharmaceuticals Ltd

Aarey Drugs Reports Q2 FY27 Standalone Net Profit of Rs. 137.01 Lakhs

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 14 Nov 2026, 06:49 PM IST  ·  BSE ID: 997e5b76-b674-43ba-b288-87dd16da1ee6
View Original BSE Filing (PDF)
💡
In Simple Terms
The drug company's board approved its Q2 FY27 results, reporting a net profit of Rs. 137.01 Lakhs for the quarter.
🤖 AI Summary
  • Board approved standalone unaudited financial results for Q2 FY27 and half year ended September 30, 2026.
  • Net profit for the quarter ended September 30, 2026, was Rs. 137.01 Lakhs.
  • Total income for Q2 FY27 was Rs. 5,024.30 Lakhs, compared to Rs. 4,634.05 Lakhs in Q1 FY27.
  • The company recorded a profit before tax of Rs. 165.96 Lakhs for Q2 FY27.
  • Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants was also noted.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
2,865.24 Lakhs
Not comparable — limited prior period data.
Total Income (Q2 FY27)
5,024.30 Lakhs
Not comparable — limited prior period data.
Profit/(Loss) for the period (Q2 FY27)
137.01 Lakhs
Not comparable — limited prior period data.
Basic EPS (Q2 FY27)
0.43 Rs.
Not comparable — limited prior period data.
Total Assets (September 30, 2026)
31,460.10 Lakhs
Total Equity (September 30, 2026)
16,966.01 Lakhs
🏢 How This Affects the Company
📈
Business Impact
The company's core business in manufacturing and trading of drugs and pharmaceuticals generated Rs. 2,865.24 Lakhs in revenue from operations during Q2 FY27.
💰
Financial Impact
Net profit for Q2 FY27 was Rs. 137.01 Lakhs, with total equity increasing to Rs. 16,966.01 Lakhs as of September 30, 2026, from Rs. 15,042.32 Lakhs on March 31, 2026.
⚙️
Operational Impact
The company purchased certain fixed assets during the reporting period, which are not yet ready for their intended use, hence no depreciation was charged on them.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results reflect the company's financial performance. Earnings per share (Basic) for Q2 FY27 are Rs. 0.43 per share.
🔍
Management Signal
The board's approval of the unaudited results indicates regular financial reporting compliance and ongoing business operations in the drug and pharmaceutical segment.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check revenue and profit trends.
Updates on utilization of funds from convertible warrants.
Status of newly acquired fixed assets becoming ready for use.
MEDIUM RISK Fluctuations in half-year revenue and unutilized fixed assets present a degree of operational uncertainty.
💡 Investor Takeaway
Aarey Drugs & Pharmaceuticals Ltd. reported a standalone net profit of Rs. 137.01 Lakhs for Q2 FY27. Total income for the quarter was Rs. 5,024.30 Lakhs. The half-year net profit was Rs. 239.38 Lakhs, compared to Rs. 239.51 Lakhs in H1 FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Total equity increased by Rs. 1,923.69 Lakhs from Rs. 15,042.32 Lakhs (March 31, 2026) to Rs. 16,966.01 Lakhs (September 30, 2026).
  • Quarterly revenue from operations grew to Rs. 2,865.24 Lakhs in Q2 FY27 from Rs. 446.25 Lakhs in Q1 FY27.

⚠️ Concerns

  • Half-year revenue from operations decreased to Rs. 13,324.99 Lakhs for H1 FY27 from Rs. 18,637.03 Lakhs for H1 FY26.
  • Trade payables (other than micro/small enterprises) decreased by Rs. 1,348.22 Lakhs to Rs. 6,810.68 Lakhs in Q2 FY27 from Rs. 8,158.90 Lakhs in Q4 FY26.
❓ Frequently Asked Questions
What was Aarey Drugs & Pharmaceuticals Ltd.'s net profit for Q2 FY27?
Aarey Drugs & Pharmaceuticals Ltd. reported a net profit of Rs. 137.01 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total income for Aarey Drugs & Pharmaceuticals Ltd. in Q2 FY27?
The total income for Aarey Drugs & Pharmaceuticals Ltd. in Q2 FY27 was Rs. 5,024.30 Lakhs.
How did Aarey Drugs & Pharmaceuticals Ltd.'s half-year revenue from operations perform?
Revenue from operations for the half year ended September 30, 2026, was Rs. 13,324.99 Lakhs, compared to Rs. 18,637.03 Lakhs for the half year ended September 30, 2025.
What were the basic earnings per share (EPS) for Aarey Drugs & Pharmaceuticals Ltd. in Q2 FY27?
The basic earnings per share for Aarey Drugs & Pharmaceuticals Ltd. in Q2 FY27 were Rs. 0.43.
What is the status of fixed assets acquired by Aarey Drugs & Pharmaceuticals Ltd.?
The company has purchased certain fixed assets that are not yet ready for their intended use as of September 30, 2026, and no depreciation has been charged on them for the current period.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel